VOR Stock Risk & Deep Value Analysis
Vor Biopharma Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About VOR Stock
We analyzed Vor Biopharma Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran VOR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
VOR Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is the binary outcome of the telitacicept Phase 3 UPSTREAM MG trial, with topline results expected in 1H 2027. Failure to meet primary endpoints in this trial would likely result in a 70-80% collapse in the company's $0.78B market capitalization, as it would severely diminish the primary asset's commercial prospects and lead to a significant cash burn with no immediate path to revenue.
Risk Matrix
Overall
Aggressive
Financial
Low
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Complete pivot in primary therapeutic focus from AML (oncology) to autoimmune diseases without detailed explanation in provided research, raising questions about prior pipeline or strategic shifts.
- ⚠
Absence of specific partnership announcements for a late-stage asset (telitacicept) in a competitive autoimmune market, which could indicate challenges in attracting collaborators or lack of external validation.
- ⚠
Heavy reliance on a single Phase 3 asset (telitacicept) for near-term value creation, making the company's ~$0.78B market cap highly susceptible to the 1H 2027 trial outcomes.
Upcoming Risk Events
- 📅
1H 2027: Negative or inconclusive topline results from the UPSTREAM MG Phase 3 trial, leading to significant market cap reduction.
- 📅
Late 2026 / Early 2027: Slower than expected enrollment or emergence of unexpected adverse safety signals in the UPSTREAM SjD trial, delaying data and increasing burn.
When to Reconsider
- 🚪
Exit if negative or ambiguous topline results from the UPSTREAM MG trial are announced (1H 2027).
- 🚪
Sell if cash, cash equivalents, and marketable securities fall below $200 million without a clear path to non-dilutive funding or revenue acceleration, indicating a shortened runway from the current ~3.5 years.
Unlock VOR Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Vor Biopharma Inc (VOR) Do?
Market Cap
$792.74M
Sector
Healthcare
Industry
Biotechnology
Employees
154
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Visit Vor Biopharma Inc WebsiteInvestment Thesis
If telitacicept's UPSTREAM MG Phase 3 trial delivers positive topline results in 1H 2027, then Vor Biopharma's $0.78B market capitalization could re-rate significantly, potentially reaching $3-5B based on projected multi-billion dollar peak sales potential in gMG and SjD. This is bullish because the current valuation does not fully price in the probability of success for a late-stage asset in large, underserved autoimmune markets, especially given the company's strong $491.5M cash position and ~3.5 year runway.
Is VOR Stock Undervalued?
Unlock the full AI analysis for VOR
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
VOR Price Targets & Strategy
12-Month Target
$65.00
Bull Case
$120.00
Bear Case
$5.00
Valuation Basis
Based on a discounted probability of success for telitacicept in gMG and SjD, implying a $3.5B market capitalization by late 2027 if Phase 3 data is positive.
Entry Strategy
Consider dollar-cost averaging between $12-$15, accumulating ahead of the 1H 2027 UPSTREAM MG topline results. Optimal entry near $10 support if market volatility provides it.
Exit Strategy
Take 50% profit at $60.00; consider full exit or significant reduction on negative Phase 3 data. Stop loss at $8.00.
Portfolio Allocation
7-15% for aggressive risk tolerance.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Does VOR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat relies on the strength and breadth of intellectual property surrounding telitacicept, its clinical success in Phase 3, and its ability to demonstrate superior efficacy or safety over existing or emerging therapies in gMG and SjD. Patent exclusivity provides a crucial, but time-limited, period of protection. Successful commercialization and patient adoption would further reinforce this through physician familiarity and prescribing habits.
Moat Erosion Risks
- •Clinical failure of telitacicept in Phase 3 trials, negating IP value for these indications.
- •Strong competition from other novel biologics or established therapies that demonstrate similar or superior efficacy/safety.
- •Patent challenges or the development of biosimilars/generics post-exclusivity period.
VOR Competitive Moat Analysis
Sign up to see competitive advantages
VOR Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. Limited broad retail investor discussion due to clinical-stage nature.
Institutional Sentiment
Neutral. Analyst ratings and institutional ownership data not provided in recent intelligence.
Insider Activity (Form 4)
No identified Form 4 filings or CEO/CFO buying/selling in the last 90 days from the provided sources.
Options Flow
Normal options activity. No specific unusual put/call ratio or large block trades identified.
Earnings Intelligence
Next Earnings
Estimated early-August 2026 (for Q2 2026)
Surprise Probability
Medium
Historical Earnings Pattern
Highly sensitive to clinical trial updates and cash runway projections, typical for a pre-revenue biotech.
Key Metrics to Watch
Competitive Position
Top Competitor
ARGNX (Argenx SE) - A leader in gMG, demonstrating strong commercial success with Vyvgart, though with a different mechanism of action (FcRn inhibitor).
Market Share Trend
Not applicable pre-commercialization. Vor aims to gain market share upon approval with a novel mechanism.
Valuation vs Peers
Trading at a discount to peers with established Phase 3 assets or approved drugs, reflecting the high binary risk before UPSTREAM MG data. If successful, current $0.78B market cap represents significant upside.
Competitive Advantages
- •Novel mechanism of action (BCMA inhibition) for gMG and SjD, potentially offering differentiated efficacy or safety profiles.
- •Late-stage (Phase 3) clinical development status, positioning it closer to market than many pipeline candidates.
- •Strong cash position ($491.5M) providing a substantial runway for trial completion without immediate dilution pressure.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive VOR Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 earnings release (estimated early August 2026): Update on UPSTREAM MG and SjD trial enrollment progress and cash burn.
- •Mid-2026: Potential announcement of partnerships or financing activities to further de-risk commercialization, if not already priced in.
Medium-Term (6-18 months)
- •1H 2027: Topline results for UPSTREAM MG Phase 3 trial (telitacicept for generalized myasthenia gravis). A positive outcome is the primary value inflection point.
- •2H 2027 - 1H 2028: Potential accelerated regulatory filing (e.g., FDA BLA) for telitacicept in gMG, contingent on positive Phase 3 data.
Long-Term (18+ months)
- •Late 2028 - 2029: Regulatory approval and commercial launch of telitacicept for gMG, targeting peak annual sales of over $1 billion.
- •Late 2027 - 2028: Topline results for UPSTREAM SjD Phase 3 trial (telitacicept for primary Sjögren’s disease), expanding market opportunity.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for VOR?
- ✓
Monitor any announcements regarding potential partnerships or licensing deals for telitacicept, which would validate its commercial potential and reduce future funding needs.
- ✓
Track quarterly operating expense burn rates; a sustained increase above $40M/quarter without corresponding progress could erode the $491.5M cash runway faster than anticipated.
Bull Case Analysis
Sign up free to see the bull case
Competing with VOR
See how Vor Biopharma Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Vor Biopharma Inc VOR | $792.7M | 8.6 | — | — | — | — | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Vor Biopharma Inc Makes Money
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for autoimmune diseases. Currently, its primary asset is telitacicept, which is in late-stage (Phase 3) clinical trials for generalized myasthenia gravis (gMG) and primary Sjögren’s disease (SjD). The company generates no commercial revenue but invests heavily in research and development to advance its drug candidates through clinical trials with the aim of eventually gaining regulatory approval and commercializing these therapies, either independently or through partnerships. Its business model hinges on achieving successful clinical outcomes and subsequent market penetration to generate substantial revenue.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Vor Biopharma Inc (VOR)?
As of May 19, 2026, Vor Biopharma Inc has a DVR Score of 8.6 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Vor Biopharma Inc?
Vor Biopharma Inc's market capitalization is approximately $792.7M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Vor Biopharma Inc use?
VOR is the ticker symbol for Vor Biopharma Inc. The company trades on the NMS.
What is the risk level for VOR stock?
Our analysis rates Vor Biopharma Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the VOR DVR analysis updated?
Our AI-powered analysis of Vor Biopharma Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 19, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for VOR (Vor Biopharma Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.